Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6006
Revised: February 2, 2014
Accepted: March 18, 2014
Published online: May 28, 2014
Core tip: The impact of antiviral therapy on clinical outcomes after curative liver resection in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains to be established. There are increasing evidence to suggest that antiviral therapy could suppress HBV replication, decrease the perioperative reactivation of virus, reduce liver injury, preserve the liver function before and after operation, and may lower the risk of HCC recurrence. Antiviral therapy may also improve the survival after liver resection by reducing recurrence and delaying the liver damage by the virus, rendering in a higher chance of receiving aggressive salvage therapy during HCC recurrence. We herein review the currently available evidences on this issue.